Mutations in RAS or FGFR3, dysregulation of MYC, deletion of p18, or loss of expression or mutation in TP53 are unique to MM and play an important role in tumor growth and the development of treatment resistance. This evidence concerns the gene TP53 and Miyoshi myopathy.